To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

March 15, 2029

Study Completion Date

December 31, 2029

Conditions

High-risk Non-muscle Invasive Bladder Cancer

Interventions

DRUG

Disitamab Vedotin for injection

Intravesical instiliations into the bladder

Trial Locations (6)

RECRUITING

Sun Yat-sen Memorial Hospital,SunYat-sen University, Guangzhou

NOT_YET_RECRUITING

Tongji Hospital, Wuhan

RECRUITING

Hunan Cancer hospital, Changsha

NOT_YET_RECRUITING

The first affiliated hospital with nanjing medical universtity, Nanjing

NOT_YET_RECRUITING

West China Hospital, Chengdu

NOT_YET_RECRUITING

Tianjin Medical University Second Hospital, Tianjin

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY